These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36995540)

  • 1. Is There a Role for Vitamin K Antagonist in the Management of Atrial Fibrillation in 2023?
    Burg MR; Ha ACT
    Curr Cardiol Rep; 2023 May; 25(5):391-399. PubMed ID: 36995540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial.
    De Caterina R; John Camm A
    Europace; 2016 Jan; 18(1):6-11. PubMed ID: 26450845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
    Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
    Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct oral anticoagulation in atrial fibrillation and heart valve surgery-a meta-analysis and systematic review.
    Gerfer S; Djordjevic I; Eghbalzadeh K; Mader N; Wahlers T; Kuhn E
    Ther Adv Cardiovasc Dis; 2022; 16():17539447221093963. PubMed ID: 35481366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic valves: A meta-analysis.
    Yokoyama Y; Briasoulis A; Ueyama H; Mori M; Iwagami M; Misumida N; Takagi H; Kuno T
    J Thorac Cardiovasc Surg; 2023 Jun; 165(6):2052-2059.e4. PubMed ID: 34417050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulation in Atrial Fibrillation Associated with Mitral Stenosis.
    da Silva RMFL
    Cardiovasc Hematol Agents Med Chem; 2022; 20(3):172-174. PubMed ID: 35319395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uninterrupted anticoagulation during catheter ablation for atrial fibrillation: no difference in major bleeding and stroke between direct oral anticoagulants and vitamin K antagonists in an updated meta-analysis of randomised controlled trials.
    Brockmeyer M; Lin Y; Parco C; Karathanos A; Krieger T; Schulze V; Heinen Y; Bejinariu A; Müller P; Makimoto H; Kelm M; Wolff G
    Acta Cardiol; 2021 May; 76(3):288-295. PubMed ID: 32056498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Oral anticoagulation in atrial fibrillation: What is the guideline for using new drugs?].
    Ibáñez Pérez de Viñaspre JA; Gómez Bitrian J; Royo Hernández R; de Azúa Jiménez M; Marco López C; Urieta González L
    Semergen; 2018; 44(5):297-303. PubMed ID: 28867369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality on DOACs Versus on Vitamin K Antagonists in Atrial Fibrillation: Analysis of the Hungarian Health Insurance Fund Database.
    Papp T; Kiss Z; Rokszin G; Fábián I; Márk L; Bagoly Z; Becker D; Merkely B; Aradi D; Dézsi CA; Járai Z; Csanádi Z
    Clin Ther; 2023 Apr; 45(4):333-346. PubMed ID: 37028991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct oral anticoagulant use in nonvalvular atrial fibrillation with valvular heart disease: a systematic review.
    Owens RE; Kabra R; Oliphant CS
    Clin Cardiol; 2017 Jun; 40(6):407-412. PubMed ID: 28004413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.
    Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A
    BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of prognostic impact of anticoagulants in heart failure patients with atrial fibrillation and renal dysfunction: direct oral anticoagulants versus vitamin K antagonists.
    Sakai T; Motoki H; Fuchida A; Takeuchi T; Otagiri K; Kanai M; Kimura K; Minamisawa M; Yoshie K; Saigusa T; Ebisawa S; Okada A; Kitabayashi H; Kuwahara K
    Heart Vessels; 2022 Jul; 37(7):1232-1241. PubMed ID: 35064298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: An updated meta-analysis.
    Ha FJ; Barra S; Brown AJ; Begley DA; Grace AA; Agarwal S
    Int J Cardiol; 2018 Jul; 262():51-56. PubMed ID: 29606512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
    Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B;
    Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study.
    Anguita Sánchez M; Bertomeu Martínez V; Ruiz Ortiz M; Cequier Fillat Á; Roldán Rabadán I; Muñiz García J; Badimón Maestro L; Esteve Pastor MA; Marín Ortuño F;
    Rev Esp Cardiol (Engl Ed); 2020 Jan; 73(1):14-20. PubMed ID: 31160265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis.
    Van Der Meersch H; De Bacquer D; De Vriese AS
    Am Heart J; 2017 Feb; 184():37-46. PubMed ID: 27892885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of 'valvular' atrial fibrillation: results of the European Heart Rhythm Association Survey.
    Potpara TS; Lip GY; Larsen TB; Madrid A; Dobreanu D; Jędrzejczyk-Patej E; Dagres N;
    Europace; 2016 Oct; 18(10):1593-1598. PubMed ID: 27876696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.